Blue Trust Inc’s Akero Therapeutics AKRO Stock Holding History

Blue Trust Inc’s Portfolio AKRO Stock Details AKRO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-13	Closed	-$617	–	2538
2025 Q3	$617	Hold	13	–	–	﹤0.01%	2391
2025 Q2	$694	Hold	13	–	–	﹤0.01%	2289
2025 Q1	$526	Hold	13	–	–	﹤0.01%	2355
2024 Q4	$362	Hold	13	–	–	﹤0.01%	2348
2024 Q3	$305	Buy	+13	New	+$339	﹤0.01%	2840

Other funds holding AKRO

DekaBank Deutsche Girozentrale Frankfurt, Germany $59.2B AUM 26.02% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Blue Trust Inc's AKRO Position: Q4 2025 in Review

Blue Trust Inc sold out of Akero Therapeutics (AKRO) in Q4 2025, closing a stake of 13 shares — an estimated $617 sold.

Blue Trust Inc first reported a position in AKRO in Q3 2024 and held it in 5 quarters. The position peaked at $694 in Q2 2025. 2 funds tracked by Wall St. Rank hold AKRO as of Q4 2025.

Blue Trust Inc reported no remaining Akero Therapeutics position as of Q4 2025 after selling out during the quarter.
Blue Trust Inc sold 13 Akero Therapeutics shares in Q4 2025, an estimated $617.
Blue Trust Inc first reported a position in Akero Therapeutics in Q3 2024 and held it in 5 quarters.
Blue Trust Inc's Akero Therapeutics position peaked at $694 in Q2 2025.
2 funds tracked by Wall St. Rank held Akero Therapeutics as of Q4 2025.

Based on Blue Trust Inc's 13F filing for Q4 2025, filed 16 Jan 2026.